VitaResc Acquisition Of Apex To Fund Septic Shock Treatment Phase III Study
Executive Summary
The acquisition of Apex Bioscience by Munich-based start-up VitaResc Biotech AG will provide for the financing of a Phase III program in nitric oxide-induced shock with Apex' lead product, pyridoxalated hemoglobin polyoxyethylene.